3 top dealmakers expect biotech M&A to stay busy in 2020. Here are the 4 key areas that are ripe for takeovers.
Business Insider -

While 2019 became the year of the megamerger in life sciences M&A, top Wall Street dealmakers don't expect that to repeat in 2020, they said Monday at the BIO CEO & Investor Conference.

But top bankers from JPMorgan Chase, Raymond James, and Centerview Partners all anticipate a busy year for dealmaking, driven by smaller acquisitions to bolster company's pipelines.

"I do anticipate more of the $1 to $5 or $1 to $10 billion deals in the next few years, rather than big pharmas becoming...

Read this story at


Related Articles